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Abstract 
Purpose of review: We review the search for genetic variants that affect the risk for alcohol 
dependence and alcohol consumption.  
Recent findings: Variations in genes affecting alcohol metabolism (ADH1B, ALDH2) are 
protective against both alcohol dependence and excessive consumption, but different variants 
are found in different populations. There are different patterns of risk variants for alcohol 
dependence vs. consumption. Variants for alcohol dependence, but not consumption, are 
associated with risk for other psychiatric illnesses. 
Summary: ADH1B and ALDH2 strongly affect both consumption and dependence. Variations in 
many other genes affect both consumption and dependence – or one or the other of these traits 
-- but individual effect sizes are small. Evidence for other specific genes that affect dependence 
is not yet strong. Most current knowledge derives from studies of European-ancestry 
populations, and large studies of carefully phenotyped subjects from different populations are 
needed to understand the genetic contributions to alcohol consumption and alcohol use 
disorders.   
 
  
Introduction 
Excessive alcohol consumption and alcohol use disorders (AUDs) take enormous tolls on 
individuals and societies. WHO estimates that 3 million deaths each year (5.3% of all deaths) 
are attributable to harmful use of alcohol, along with 5.1% of the global burden of disease1. 
About 50% of the liability for AUDs is heritable2, but – as is typical for complex genetic traits – 
the genetic risk is spread among a large number of variants in many genes, with most variants 
having very small effects (genetic risk ratios < 1.05). Despite AUDs being associated with two of 
the strongest single-locus genetic effects observed in psychiatry – of functional variants in the 
alcohol dehydrogenase (ADH1B) and aldehyde dehydrogenase 2 (ALDH2) genes – the 
identification of additional loci of smaller effect has been difficult. Key functional variants in 
ADH1B increase the rate at which ethanol is metabolized into acetaldehyde (which has aversive 
effects), and a functional variant in ALDH2 essentially blocks its ability to remove acetaldehyde, 
leading to a strong aversive reaction3. These variants reduce excessive drinking by causing 
aversive reactions, and thereby reduce the risk for AUDs. Disulfiram inhibits ALDH2 and thereby 
causes an aversive reaction that strongly reduces drinking3. 
The difficulty in identifying other loci of smaller effect is in part due to heterogeneity of the 
disorder. A diagnosis of AUD, under the current DSM-5 system4, is obtained when an individual 
endorses 2 or more of 11 possible criteria that encompass not just aspects of excessive drinking 
(e.g., tolerance, drinking larger amounts or for longer than expected) but also loss of control 
over drinking (e.g., giving up important activities to drink) and drinking despite serious physical 
and emotional consequences. There are many different combinations of symptoms of varying 
nature and severity that can result in an AUD diagnosis, which might be due to different 
constellations of genetic effects and thereby contribute to the difficulty in gene discovery. 
Additionally, we expect most risk variants relevant for alcohol use behaviors to have small to 
very small effect sizes. Population heterogeneity is also a factor: different populations may have 
different risk variants or even different risk genes. These three factors (among others) affect 
most complex genetic traits, raising the difficulty of gene identification. To overcome these 
fundamental challenges and elucidate the genetic contributions to risk, large sample sizes will 
be necessary. But obtaining large samples in which AUDs have been carefully assessed has 
proven difficult. It is far easier to obtain large samples with data on alcohol consumption, but 
that does not address key issues relevant to dependence. Most individuals who drink do not 
become dependent; in the US, about 12% of those who drink alcohol meet criteria for alcohol 
dependence at some point in their lives5. These non-dependent drinkers contribute the bulk of 
the data for population-based samples where AUD per se is not assessed. 
Although there have been many candidate gene studies directed at AUDs, most have been 
equivocal. The most robust associations were the effects of functional variants in alcohol 
dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) genes that affect alcohol 
metabolism3, 6-13 (Figure 1). These findings are among the very few that have survived from the 
candidate gene era to today’s era of genome-wide studies. Variants in ADH1B and ADH1C that 
increase the rate of oxidation of ethanol to acetaldehyde, and variants in ALDH2 that decrease 
the rate of acetaldehyde oxidation to acetate, exert strong protective effects3 (Figure 1). The 
frequencies of these variants, and therefore the effects they exert on risk, differ greatly among 
populations, with the ALDH2 variant (rs671) common in East Asia but rare outside Asia3. 
Similarly, one functional variant in ADH1B (rs1229984) is common in East Asia (>70%), less 
common in populations from the Middle East (~20%), even less common in Europe (<4%) and 
rare or even absent in Africa3. A different functional variant in ADH1B (rs2066702) is relatively 
common in many populations from Africa (up to 28%) but rare elsewhere3. These variants exert 
a degree of protection via enzymatic regulation of rapid conversion of alcohol to acetaldehyde 
(ADH) or reduced clearance of acetaldehyde to acetate (ALDH), with accumulating 
acetaldehyde resulting in aversive sensations upon alcohol intake.  
Recent studies 
Variants mapped to ADH and ALDH genes exert strong effects, but much of the variation in risk 
for AUDs and also alcohol consumption lies elsewhere in the genome. Genomewide association 
studies (GWAS) have sought to identify those variants. Some have focused on alcohol 
consumption (e.g., drinks/week), which is a measure relatively easy to obtain. Because of the 
wide recognition of the medical consequences of alcohol use, such measures are available 
even in many studies unrelated to addictions. There are difficulties with drinks/week as a 
phenotype, however: it may be asked of a recent period (week, month), a typical period during 
the past year, or the period of maximum consumption during the lifetime. These may differ quite 
a bit, and short-term or unrepresentative periods may miss information more closely related to 
problem drinking episodes, or even represent them inaccurately (e.g., reductions in recent 
drinking due to treatment). For genetic studies, we really want information about trait, rather 
than state. Lifetime dependence diagnoses are trait measures; current alcohol consumption is a 
state measure. The disparity between typical and problematic consumption is further widened in 
most population-representative samples, in which most of the individuals are at the low end of 
the intake spectrum; thus genetic discoveries might relate more closely to determinants of low 
levels of drinking.  
Nonetheless, GWAS of alcohol consumption have been successful at identifying loci. Two large 
meta-analyses identified variants in AUTS214 and KLB15. The largest published GWAS of 
alcohol consumption was conducted with data on 112,117 participants from the UK Biobank16; it 
identified 14 loci, including variants in ADH1B/ADH1C/ADH5 (likely due to the functional variant 
in ADH1B3), KLB, GCKR, CADM2, FAM69C, STPG2 and DNAJB14; gene-based analyses also 
implicated DRD2 and PDE4B. [Larger ones are expected soon.] Using a slightly expanded set 
of items, another GWAS of the consumption subscale of the Alcohol Use Disorders 
Identification Test17 (AUDIT-C, questions 1-3, quantity and frequency of drinking) found 
additional novel variants in CPS1 and RFC113.  
A recent large GWAS13 and meta-analysis of total AUDIT scores in subjects from the UK 
Biobank and 23andme also showed significant SNPs in the ADH1B region, replicated KLB and 
GCKR, and revealed novel loci including JCAD, CRHR1 and SLC39A13. Working with the UK 
Biobank data, the authors suggest that total AUDIT score – which goes beyond consumption 
and includes measures of medical harm as well (see below) -- can be used as a proxy for 
dependence, with the best balance of higher numbers and reasonable specificity when controls 
are defined as AUDIT ≤ 4 and cases as AUDIT ≥ 12. This study is among the first to delineate 
the genetic distinctions between consumption and problem drinking in a large population cohort. 
There were important differences between the AUDIT-C and the AUDIT-P (questions 4-10, 
which asks about problems arising from excessive drinking, such as guilt or remorse after 
drinking, inability to stop drinking, failure to do what was expected due to drinking, and memory 
loss/blackouts and injuries during drinking). Some loci were common to both, including SNPs in 
the ADH region that conditional analyses indicated were driven by ADH1B (rs1229984), but 
some loci were specific to only one sub-scale. AUDIT-C showed stronger genetic correlation 
with alcohol consumption (rg = 0.92, vs. 0.76 for AUDIT-P)13. The genetic correlation between 
AUDIT-P and alcohol dependence (rg = 0.63) was far greater than the correlation with either 
total AUDIT (rg = 0.39) or AUDIT-C (rg = 0.33). Notably, AUDIT-P showed significant positive 
genomewide genetic correlations with several psychiatric disorders, including higher risk for 
depression, and with higher neuroticism, lower educational achievement and lower subjective 
well-being. On the other hand, higher genetic liability to the AUDIT-C was related to lower 
genetic risk for depression and to higher educational achievement13.  
In an interesting twist on the usual approach, a study from the VA Million Veteran Program used 
the firmly established association of ADH1B (rs1229984 in European Americans, rs2066702 in 
African Americans12) to examine how AUDIT-C and ICD codes perform as phenotypes for 
harmful alcohol use18. They determined that in the veteran population, high (≥8) age-adjusted 
AUDIT-C score correlated better than ICD diagnostic codes with the ADH1B variants.  
Alcohol dependence is a more severe form of AUD (i.e., 3 or more of 7 criteria in DSM-IV), that 
affects about 10-12% of drinkers. It is a serious psychiatric disorder that is ascertained by much 
more detailed interviews than the AUDIT (e.g. SSAGA19, SSADDA20). Since detailed 
ascertainment requires more effort and is therefore more costly, it is used less frequently than 
simple state measures of quantity and frequency of use, such as the AUDIT-C. There have 
been several GWAS of alcohol dependence as well as of criterion counts (Table 1). Many have 
been relatively small (especially when compared to large biobank studies), and findings have 
been mixed, with limited replication. Notably, several of the first GWAS failed to identify 
rs1229984 in ADH1B, despite its well-documented role. This gap was likely due to both 
technical challenges (rs1229984 was not on most GWAS arrays and is poorly imputed on some 
of them) and its relatively low allele frequency in the predominantly European populations that 
were being investigated3. It is common in many Asian populations, and studies there have 
consistently shown its impact3. A targeted genotyping study7 and a later GWAS and meta-
analysis demonstrated the effect of rs1229984 on alcohol dependence8.  
The most recent and largest GWAS of alcohol dependence was led by the Psychiatric 
Genomics Consortium; it included 14,904 cases and 37,944 alcohol-exposed controls12. This 
study again unequivocally implicated ADH1B in the etiology of alcohol dependence, both in 
Europeans (rs1229984; p = 9.8 x 10-13) and African-Americans (rs2066702; p = 2.2 x 10-9). An 
important finding was a confirmation that different variants in ADH1B, both of which result in 
amino acid substitutions that have similar effects on alcohol metabolism, were found in the two 
populations, as a result of large differences in their frequencies and LD patterns. Despite the 
limited discovery of novel loci, this recent GWAS provided four notable insights. First, it 
identified genetic correlations between alcohol dependence and a range of psychiatric disorders 
(e.g., schizophrenia, depression), substance use (e.g., tobacco and cannabis smoking), 
sociodemographic factors (e.g., education attainment, neighborhood deprivation) and behavioral 
features (e.g., neuroticism, well-being, age at the birth of one’s first child). Second, despite the 
substantially smaller sample size of the African-American subset of the data, polygenic risk 
scores derived from this subset were superior predictors (1.7%; p = 1.9 x 10-7) of alcohol 
dependence in an independent African-American sample than were risk scores from the much 
larger European discovery GWAS (0.37%; p = 0.01), confirming the substantial ancestral 
specificity that was implied by the discovery of different lead SNPs in African-Americans vs. 
Europeans. Third, the genetic correlation with alcohol consumption was modest and variable 
(0.37 to 0.70). This is, again, a demonstration that there are many genes that affect dependence 
above and beyond those affecting consumption in the general population. Fourth, despite twin 
studies suggesting a heritability of 50%, common SNPs explained only 9% of the variance in 
alcohol dependence. This low SNP-h2 is consistent with every other psychiatric disorder that 
has been studied to date, and is expected to increase with increasing sample size and better 
genomic coverage.  
Even though the protective effect of functional loci in ADH1B on risk for AUDs is unequivocal, by 
itself it does not determine risk. The protective effect of the minor allele of rs1229984 on the 
transition to first intoxication and first DSM-5 symptom is dampened in the presence of drinking 
peers21, and childhood trauma moderates the effects of this variant22. 
 
A Genetic View of Comorbidity with Depression 
The co-occurrence of AUD and depression is significant, with a nearly doubling of the risk of 
either disorder in those with the other23. From a clinical viewpoint, the etiology of the elevated 
co-occurrence of AUD and depression is of considerable importance as treatment for such a 
dual diagnosis is particularly challenging24. AUD can occur secondary to a diagnosis of 
depression25, and AUD can result in depression26; that is, there are cases where one of these 
disorders seems to cause the other one. But some of this co-occurrence appears to reflect 
common genetic liabilities27, 28. In the PGC study of alcohol dependence, the SNP based genetic 
correlation with major depressive disorder (SNP-rg = 0.56), depressive symptoms (SNP-rg = 
0.60) and neuroticism (SNP-rg = 0.44) were strong and could indicate shared pathways or 
networks12. One study used alcohol dependence and depression criterion counts to identify a 
genomewide significant variant in semaforin 3A (SEM3A) in African-Americans29. Even after 
accounting for individuals with comorbid AUD, polygenic risk scores (PRS, sometimes called a 
genetic risk score (GRS), represent the weighted additive effect of multiple independent loci) 
derived from a large GWAS of major depression predicted up to 2% of the variance in alcohol 
dependence even after accounting for pleiotropic effects30. A collaboration between the 
Psychiatric Genomics Consortium’s Substance Use Disorders and Major Depressive Disorders 
working groups recently examined whether high polygenic risk for AUD might be associated 
with risk for depression, or vice versa, and found that genetic risk for depression exerted a 
putatively causal effect on liability for alcohol dependence, but not consistently so on quantity or 
frequency measures of alcohol intake31. While this study provides genetically-informed evidence 
for a causal role of depression in the etiology of pathological drinking, it did not exclude the 
reverse pathway from alcohol dependence to depression due to differences in sample size 
across the two studies. These studies pave the way for larger, analyses that might lead to better 
delineation of the genetic contributions to this comorbidity. But we should not expect a definitive 
answer with respect to presence of one direction of causation and not the other; that simply is 
not consistent with clinical observation. 
Looking ahead 
AUD is a polygenic trait with effect sizes that are closer to the smaller effects observed for major 
depressive disorder (MDD) than for schizophrenia (SCZ), both also heritable and complex 
psychiatric disorders.12 Thus, our expectation is that unlike SCZ where ~37,000 cases resulted 
in the identification of 108 loci32, results for AUD will follow the discovery pathway for MDD, 
where ~136,000 cases were required to identify 44 loci33. What does this mean for ongoing 
gene-identification efforts? To reach the large numbers needed, many studies with different 
levels of phenotyping, from structured diagnostic interview instruments (e.g., SSAGA, 
SSADDA), ICD codes derived from electronic health records, and brief screening tools (e.g., 
AUDIT, CAGE34) will need to be combined. This will result in substantial heterogeneity, and the 
likelihood of some undetected cases among those assigned as controls due to low specificity. 
Taking the results from such large studies back to carefully phenotyped samples will be 
necessary to understand the findings better. More studies of ethnically diverse cohorts are 
needed to better cover the range of variations relevant beyond Europeans; different groups are 
known to have different variants and allele frequencies, as well as different environments in 
which they act3, 12, 35.  
Another important observation is that only 9% of the heritability of alcohol dependence was 
explained by available genome-wide SNPs, despite twin studies indicating that this estimate 
should be closer to 50%. This observation holds for alcohol consumption and also for nearly all 
other complex psychiatric phenotypes. One reason for this discrepancy is that twin studies rely 
on assumptions that may inflate heritability estimates (e.g., random mating). Alternatively, 
because genome-wide arrays mostly capture common variants, any heritable variation that is 
attributable to rarer variants or to structural variants (e.g., copy number variants) is likely to be 
missed in SNP-based heritability calculations. Additionally, standard GWAS analyses do not 
take interacting loci into account. A recent paper suggests that as our ability to infer such 
unmeasured variation improves, more of the heritability of complex traits will be captured36.  
The impact of individual genes (other than ADH1B and ALDH23) is individually very small but 
cumulatively large. Aggregating the weighted effect of tens of thousands or millions of variants 
into a PRS can provide a partial index of vulnerability (or resilience). Even such large 
aggregates of genetic effects have modest predictive power, but they do enable examination of 
how genetics and environment can interact, and potentially how one can better match 
prevention and treatment options to an individual. It must, however, be kept in mind that genes 
do not themselves determine whether someone will become alcoholic. Individuals at high 
polygenic risk may elect not to consume alcohol and those at low polygenic risk may experience 
serious life events or other environmental influences that propel them towards AUD. Even in this 
exciting new era of gene discovery, it is critical to highlight that genetic risk is only a piece of the 
complex architecture of risk and protective factors that underlie AUD. Some of these may be 
amenable to treatment interventions. It is reasonable to expect that better knowledge of the 
genetic risk and protective factors involved may bring such treatment closer to clinical reality. 
 
  
Table 1: GWAS studies of alcohol use disorders to date. DSM-IV AD = DSM-IV alcohol 
dependence; DSM-IV AA – DSM-IV alcohol abuse; AUDIT score = total AUDIT score; AUDIT-C 
= score on AUDIT questions 1-3 (consumption); AUDIT-P = score on AUDIT questions 4-10 
(problems); *=not significant at the standard level of 5 x 10-8. 
 
Author 
(year) 
Ncase/Ncontrol 
Definition of 
AUD Significant variants  Gene European African-American Other 
Treutlein37 
(2009) 1460/2332  - - DSM-IV AD 
rs7590720, 
rs1344694 PECR 
Bierut38 
(2010) 1235/1433 662/499 - DSM-IV AD - - 
Edenberg39 
(2010) 847/552 345/140 - DSM-IV AD - - 
Wang40 
(2013) 
2322 
subjects from 
118 families 
- - 
DSM-IV AD 
criterion 
count 
- - 
Heath41 
(2011) 8209 - - 
DSM-IV AD 
and DSM-IV 
AA criteria 
factor score 
- - 
Kendler42 
(2011) 2357 812 - 
Alcohol 
dependence 
factor score 
- - 
Frank43 
(2012) 1333/2168 - - DSM-IV AD rs1789891 ADH1C 
Zuo44 
(2012) 1409/1518 681/508 - DSM-IV AD - - 
McGue45 
(2013) 7188 - - 
DSM 
symptoms 
and non-
diagnostic 
problems 
factor score 
    
Park10 
(2013) - - 
Korean 
(621/750) DSM-IV AD 
rs1442492*   
rs10516441* ADH7 
rs671* ALDH2 
Gelernter8 
(2014) 5131 4629 - 
DSM-IV AD 
criterion 
count 
rs1229984  
rs2066702  ADH1B, 
rs10031423  PDLIM5 
rs116203444 LOC100507053 
rs28470942    
rs925966   
rs1493464   
rs1856202   
rs113683471  
Quillen46 
(2014) - - 
Chinese 
DSM-IV AD 
rs3782886   
(122/473) rs671 ALDH2 
Kapoor47 
(2014) 
1788 from 
118 families - - 
Age at 
onset of AD 
rs2168784 Intergenic 
rs35951/rs35952 ARL15 
rs57083693 UTP20 
Mbarek48 
(2015) 1,374/6,468   - 
AUDIT 
- - ≥9 (men); 
≥6 (women) 
Adkins49 
(2017) 706/1,748 - - DSM-IV AD 
rs2256485 COL6A3 
rs150268941 
Sanchez-
Roige50 
(2017) 
20,328 
- - AUDIT score - - 
Almli51 
(2017)   1036   
AUDIT 
score rs1433375 SCLT1 
Sanchez-
Roige13 
(2018) 
141,923 - - 
AUDIT 
score, 
AUDIT-C & 
AUDIT-P 
rs4953148 LINC01833 
rs1260326 GCKR/SNX17 
rs1920650 (many) 
rs11940694  KLB 
rs146788033 METAP1 
rs11733695 RP11-696N14.1 
rs3114045 ADH1C 
rs188514326 RP11-588P8.1 
rs13135092 SLC39A8, RN7SL728P 
rs35040843 RP11-700E23.3 
rs7078436 JCAD 
rs2293576 (many) 
rs62062288 CRHR1 & many 
rs492602 (many) 
   
Gelernter9 
(2018) - - 
Thai: DSM-IV AD 
criterion 
count  
rs149212747 ALDH2 & SH2B3 
1045 
Walters12 
(2018) 11569/34,999 3335/2945   DSM-IV AD 
rs1229984 (EA) & 
rs2066702 (AA) ADH1B (both alleles) 
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